The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Neurodegenerative Drugs Market Research Report 2024
Synopsis
Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
The global Neurodegenerative Drugs market was valued at US$ 115030 million in 2023 and is anticipated to reach US$ 173000 million by 2030, witnessing a CAGR of 5.9% during the forecast period 2024-2030.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Drugs.
Report Scope
The Neurodegenerative Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Segment by Application
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neurodegenerative Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Neurodegenerative drugs are medications used to manage and alleviate symptoms associated with neurodegenerative diseases. They may target various aspects of disease progression, such as cognitive function, motor symptoms, and inflammation.
The global Neurodegenerative Drugs market was valued at US$ 115030 million in 2023 and is anticipated to reach US$ 173000 million by 2030, witnessing a CAGR of 5.9% during the forecast period 2024-2030.
The market for neurodegenerative drugs is driven by the growing burden of neurodegenerative diseases and the need for effective and disease-modifying treatments. The market's growth is also influenced by ongoing research in neuroscience and the development of novel drug candidates targeting specific neurodegenerative pathways.
This report aims to provide a comprehensive presentation of the global market for Neurodegenerative Drugs, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Neurodegenerative Drugs.
Report Scope
The Neurodegenerative Drugs market size, estimations, and forecasts are provided in terms of sales volume (MT) and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Neurodegenerative Drugs market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Neurodegenerative Drugs manufacturers, new entrants, and industry chain related companies in this market with information on the revenues, sales volume, and average price for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Novartis
Pfizer
Merck Serono
Biogen Idec
TEVA
UCB
Boehringer Ingelheim
Sanofi
GlaxoSmithKline
Livzon Pharmaceutical
Haisco Pharmaceutical
Jingxin Pharmaceutical
Dongcheng Biochemicals
Hisun Pharmaceutical
Luye Pharma
Ark Pharmaceutical
Kanghong Pharmaceutical
Huahai Pharmaceutical
BORA PHARMACEUTICALS
Segment by Type
NMDA
SSRIs
Dopamine Inhibitors
Segment by Application
Parkinson’s Disease
Huntington Disease
Amyotrophic Lateral Sclerosis
Alzheimer’s Disease
Consumption by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Indonesia
Thailand
Malaysia
Latin America
Mexico
Brazil
Argentina
Middle East & Africa
Turkey
Saudi Arabia
UAE
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by region, by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Detailed analysis of Neurodegenerative Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 3: Sales, revenue of Neurodegenerative Drugs in regional level and country level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and market size of each country in the world.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 7: Analysis of industrial chain, including the upstream and downstream of the industry.
Chapter 8: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.
Chapter 9: The main points and conclusions of the report.
Index1 Neurodegenerative Drugs Market Overview
1.1 Product Overview and Scope of Neurodegenerative Drugs
1.2 Neurodegenerative Drugs Segment by Type
1.2.1 Global Neurodegenerative Drugs Market Value Comparison by Type (2024-2030)
1.2.2 NMDA
1.2.3 SSRIs
1.2.4 Dopamine Inhibitors
1.3 Neurodegenerative Drugs Segment by Application
1.3.1 Global Neurodegenerative Drugs Market Value by Application: (2024-2030)
1.3.2 Parkinson’s Disease
1.3.3 Huntington Disease
1.3.4 Amyotrophic Lateral Sclerosis
1.3.5 Alzheimer’s Disease
1.4 Global Neurodegenerative Drugs Market Size Estimates and Forecasts
1.4.1 Global Neurodegenerative Drugs Revenue 2019-2030
1.4.2 Global Neurodegenerative Drugs Sales 2019-2030
1.4.3 Global Neurodegenerative Drugs Market Average Price (2019-2030)
1.5 Assumptions and Limitations
2 Neurodegenerative Drugs Market Competition by Manufacturers
2.1 Global Neurodegenerative Drugs Sales Market Share by Manufacturers (2019-2024)
2.2 Global Neurodegenerative Drugs Revenue Market Share by Manufacturers (2019-2024)
2.3 Global Neurodegenerative Drugs Average Price by Manufacturers (2019-2024)
2.4 Global Neurodegenerative Drugs Industry Ranking 2022 VS 2023 VS 2024
2.5 Global Key Manufacturers of Neurodegenerative Drugs, Manufacturing Sites & Headquarters
2.6 Global Key Manufacturers of Neurodegenerative Drugs, Product Type & Application
2.7 Neurodegenerative Drugs Market Competitive Situation and Trends
2.7.1 Neurodegenerative Drugs Market Concentration Rate
2.7.2 The Global Top 5 and Top 10 Largest Neurodegenerative Drugs Players Market Share by Revenue
2.7.3 Global Neurodegenerative Drugs Market Share by Company Type (Tier 1, Tier 2 and Tier 3)
2.8 Manufacturers Mergers & Acquisitions, Expansion Plans
3 Neurodegenerative Drugs Retrospective Market Scenario by Region
3.1 Global Neurodegenerative Drugs Market Size by Region: 2019 Versus 2023 Versus 2030
3.2 Global Neurodegenerative Drugs Global Neurodegenerative Drugs Sales by Region: 2019-2030
3.2.1 Global Neurodegenerative Drugs Sales by Region: 2019-2024
3.2.2 Global Neurodegenerative Drugs Sales by Region: 2025-2030
3.3 Global Neurodegenerative Drugs Global Neurodegenerative Drugs Revenue by Region: 2019-2030
3.3.1 Global Neurodegenerative Drugs Revenue by Region: 2019-2024
3.3.2 Global Neurodegenerative Drugs Revenue by Region: 2025-2030
3.4 North America Neurodegenerative Drugs Market Facts & Figures by Country
3.4.1 North America Neurodegenerative Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.4.2 North America Neurodegenerative Drugs Sales by Country (2019-2030)
3.4.3 North America Neurodegenerative Drugs Revenue by Country (2019-2030)
3.4.4 United States
3.4.5 Canada
3.5 Europe Neurodegenerative Drugs Market Facts & Figures by Country
3.5.1 Europe Neurodegenerative Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.5.2 Europe Neurodegenerative Drugs Sales by Country (2019-2030)
3.5.3 Europe Neurodegenerative Drugs Revenue by Country (2019-2030)
3.5.4 Germany
3.5.5 France
3.5.6 U.K.
3.5.7 Italy
3.5.8 Russia
3.6 Asia Pacific Neurodegenerative Drugs Market Facts & Figures by Country
3.6.1 Asia Pacific Neurodegenerative Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.6.2 Asia Pacific Neurodegenerative Drugs Sales by Country (2019-2030)
3.6.3 Asia Pacific Neurodegenerative Drugs Revenue by Country (2019-2030)
3.6.4 China
3.6.5 Japan
3.6.6 South Korea
3.6.7 India
3.6.8 Australia
3.6.9 China Taiwan
3.6.10 Indonesia
3.6.11 Thailand
3.6.12 Malaysia
3.7 Latin America Neurodegenerative Drugs Market Facts & Figures by Country
3.7.1 Latin America Neurodegenerative Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.7.2 Latin America Neurodegenerative Drugs Sales by Country (2019-2030)
3.7.3 Latin America Neurodegenerative Drugs Revenue by Country (2019-2030)
3.7.4 Mexico
3.7.5 Brazil
3.7.6 Argentina
3.8 Middle East and Africa Neurodegenerative Drugs Market Facts & Figures by Country
3.8.1 Middle East and Africa Neurodegenerative Drugs Market Size by Country: 2019 VS 2023 VS 2030
3.8.2 Middle East and Africa Neurodegenerative Drugs Sales by Country (2019-2030)
3.8.3 Middle East and Africa Neurodegenerative Drugs Revenue by Country (2019-2030)
3.8.4 Turkey
3.8.5 Saudi Arabia
3.8.6 UAE
4 Segment by Type
4.1 Global Neurodegenerative Drugs Sales by Type (2019-2030)
4.1.1 Global Neurodegenerative Drugs Sales by Type (2019-2024)
4.1.2 Global Neurodegenerative Drugs Sales by Type (2025-2030)
4.1.3 Global Neurodegenerative Drugs Sales Market Share by Type (2019-2030)
4.2 Global Neurodegenerative Drugs Revenue by Type (2019-2030)
4.2.1 Global Neurodegenerative Drugs Revenue by Type (2019-2024)
4.2.2 Global Neurodegenerative Drugs Revenue by Type (2025-2030)
4.2.3 Global Neurodegenerative Drugs Revenue Market Share by Type (2019-2030)
4.3 Global Neurodegenerative Drugs Price by Type (2019-2030)
5 Segment by Application
5.1 Global Neurodegenerative Drugs Sales by Application (2019-2030)
5.1.1 Global Neurodegenerative Drugs Sales by Application (2019-2024)
5.1.2 Global Neurodegenerative Drugs Sales by Application (2025-2030)
5.1.3 Global Neurodegenerative Drugs Sales Market Share by Application (2019-2030)
5.2 Global Neurodegenerative Drugs Revenue by Application (2019-2030)
5.2.1 Global Neurodegenerative Drugs Revenue by Application (2019-2024)
5.2.2 Global Neurodegenerative Drugs Revenue by Application (2025-2030)
5.2.3 Global Neurodegenerative Drugs Revenue Market Share by Application (2019-2030)
5.3 Global Neurodegenerative Drugs Price by Application (2019-2030)
6 Key Companies Profiled
6.1 Novartis
6.1.1 Novartis Corporation Information
6.1.2 Novartis Description and Business Overview
6.1.3 Novartis Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.1.4 Novartis Neurodegenerative Drugs Product Portfolio
6.1.5 Novartis Recent Developments/Updates
6.2 Pfizer
6.2.1 Pfizer Corporation Information
6.2.2 Pfizer Description and Business Overview
6.2.3 Pfizer Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.2.4 Pfizer Neurodegenerative Drugs Product Portfolio
6.2.5 Pfizer Recent Developments/Updates
6.3 Merck Serono
6.3.1 Merck Serono Corporation Information
6.3.2 Merck Serono Description and Business Overview
6.3.3 Merck Serono Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.3.4 Merck Serono Neurodegenerative Drugs Product Portfolio
6.3.5 Merck Serono Recent Developments/Updates
6.4 Biogen Idec
6.4.1 Biogen Idec Corporation Information
6.4.2 Biogen Idec Description and Business Overview
6.4.3 Biogen Idec Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Biogen Idec Neurodegenerative Drugs Product Portfolio
6.4.5 Biogen Idec Recent Developments/Updates
6.5 TEVA
6.5.1 TEVA Corporation Information
6.5.2 TEVA Description and Business Overview
6.5.3 TEVA Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.5.4 TEVA Neurodegenerative Drugs Product Portfolio
6.5.5 TEVA Recent Developments/Updates
6.6 UCB
6.6.1 UCB Corporation Information
6.6.2 UCB Description and Business Overview
6.6.3 UCB Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.6.4 UCB Neurodegenerative Drugs Product Portfolio
6.6.5 UCB Recent Developments/Updates
6.7 Boehringer Ingelheim
6.6.1 Boehringer Ingelheim Corporation Information
6.6.2 Boehringer Ingelheim Description and Business Overview
6.6.3 Boehringer Ingelheim Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.4.4 Boehringer Ingelheim Neurodegenerative Drugs Product Portfolio
6.7.5 Boehringer Ingelheim Recent Developments/Updates
6.8 Sanofi
6.8.1 Sanofi Corporation Information
6.8.2 Sanofi Description and Business Overview
6.8.3 Sanofi Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.8.4 Sanofi Neurodegenerative Drugs Product Portfolio
6.8.5 Sanofi Recent Developments/Updates
6.9 GlaxoSmithKline
6.9.1 GlaxoSmithKline Corporation Information
6.9.2 GlaxoSmithKline Description and Business Overview
6.9.3 GlaxoSmithKline Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.9.4 GlaxoSmithKline Neurodegenerative Drugs Product Portfolio
6.9.5 GlaxoSmithKline Recent Developments/Updates
6.10 Livzon Pharmaceutical
6.10.1 Livzon Pharmaceutical Corporation Information
6.10.2 Livzon Pharmaceutical Description and Business Overview
6.10.3 Livzon Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.10.4 Livzon Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.10.5 Livzon Pharmaceutical Recent Developments/Updates
6.11 Haisco Pharmaceutical
6.11.1 Haisco Pharmaceutical Corporation Information
6.11.2 Haisco Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.11.3 Haisco Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.11.4 Haisco Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.11.5 Haisco Pharmaceutical Recent Developments/Updates
6.12 Jingxin Pharmaceutical
6.12.1 Jingxin Pharmaceutical Corporation Information
6.12.2 Jingxin Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.12.3 Jingxin Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.12.4 Jingxin Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.12.5 Jingxin Pharmaceutical Recent Developments/Updates
6.13 Dongcheng Biochemicals
6.13.1 Dongcheng Biochemicals Corporation Information
6.13.2 Dongcheng Biochemicals Neurodegenerative Drugs Description and Business Overview
6.13.3 Dongcheng Biochemicals Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.13.4 Dongcheng Biochemicals Neurodegenerative Drugs Product Portfolio
6.13.5 Dongcheng Biochemicals Recent Developments/Updates
6.14 Hisun Pharmaceutical
6.14.1 Hisun Pharmaceutical Corporation Information
6.14.2 Hisun Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.14.3 Hisun Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.14.4 Hisun Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.14.5 Hisun Pharmaceutical Recent Developments/Updates
6.15 Luye Pharma
6.15.1 Luye Pharma Corporation Information
6.15.2 Luye Pharma Neurodegenerative Drugs Description and Business Overview
6.15.3 Luye Pharma Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.15.4 Luye Pharma Neurodegenerative Drugs Product Portfolio
6.15.5 Luye Pharma Recent Developments/Updates
6.16 Ark Pharmaceutical
6.16.1 Ark Pharmaceutical Corporation Information
6.16.2 Ark Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.16.3 Ark Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.16.4 Ark Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.16.5 Ark Pharmaceutical Recent Developments/Updates
6.17 Kanghong Pharmaceutical
6.17.1 Kanghong Pharmaceutical Corporation Information
6.17.2 Kanghong Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.17.3 Kanghong Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.17.4 Kanghong Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.17.5 Kanghong Pharmaceutical Recent Developments/Updates
6.18 Huahai Pharmaceutical
6.18.1 Huahai Pharmaceutical Corporation Information
6.18.2 Huahai Pharmaceutical Neurodegenerative Drugs Description and Business Overview
6.18.3 Huahai Pharmaceutical Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.18.4 Huahai Pharmaceutical Neurodegenerative Drugs Product Portfolio
6.18.5 Huahai Pharmaceutical Recent Developments/Updates
6.19 BORA PHARMACEUTICALS
6.19.1 BORA PHARMACEUTICALS Corporation Information
6.19.2 BORA PHARMACEUTICALS Neurodegenerative Drugs Description and Business Overview
6.19.3 BORA PHARMACEUTICALS Neurodegenerative Drugs Sales, Revenue and Gross Margin (2019-2024)
6.19.4 BORA PHARMACEUTICALS Neurodegenerative Drugs Product Portfolio
6.19.5 BORA PHARMACEUTICALS Recent Developments/Updates
7 Industry Chain and Sales Channels Analysis
7.1 Neurodegenerative Drugs Industry Chain Analysis
7.2 Neurodegenerative Drugs Key Raw Materials
7.2.1 Key Raw Materials
7.2.2 Raw Materials Key Suppliers
7.3 Neurodegenerative Drugs Production Mode & Process
7.4 Neurodegenerative Drugs Sales and Marketing
7.4.1 Neurodegenerative Drugs Sales Channels
7.4.2 Neurodegenerative Drugs Distributors
7.5 Neurodegenerative Drugs Customers
8 Neurodegenerative Drugs Market Dynamics
8.1 Neurodegenerative Drugs Industry Trends
8.2 Neurodegenerative Drugs Market Drivers
8.3 Neurodegenerative Drugs Market Challenges
8.4 Neurodegenerative Drugs Market Restraints
9 Research Finding and Conclusion
10 Methodology and Data Source
10.1 Methodology/Research Approach
10.1.1 Research Programs/Design
10.1.2 Market Size Estimation
10.1.3 Market Breakdown and Data Triangulation
10.2 Data Source
10.2.1 Secondary Sources
10.2.2 Primary Sources
10.3 Author List
10.4 Disclaimer
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
